Breaking News Instant updates and real-time market news.

CDEV

Centennial Resource Development

$7.50 /

-0.375 (-4.76%)

07:10
05/19/22
05/19
07:10
05/19/22
07:10

Centennial Resource, Colgate Energy to combine in merger of equals

Centennial Resource Development and Colgate Energy Partners III announced they have entered into an agreement to combine in a merger of equals transaction. The combined company will be the largest pure-play E&P company in the Delaware Basin with approximately 180,000 net leasehold acres, 40,000 net royalty acres and total current production of approximately 135,000 Boe/d. The combined company plans to leverage its high-quality, scaled asset base to drive leading shareholder returns. Key Highlights: High-quality, complementary asset base with differentiated inventory depth to support sustainable free cash flow growth; Positioned to significantly increase cash returns to shareholders, with over $1 billion of expected free cash flow in 2023 at current strip prices; Highly accretive to key financial metrics, including cash flow, free cash flow and net asset value per share; Strong balance sheet with expected leverage below 1.0x at year-end 2022; Sean Smith to serve as Executive Chair of the Board; Will Hickey and James Walter to serve as Co-CEOs; Significant equity ownership of combined management team aligns with shareholders; Shared commitment to prioritizing ESG with continued focus on reducing environmental impact. The approximately $7.0 billion merger of equals values Colgate at approximately $3.9 billion and is comprised of 269.3 million shares of Centennial stock, $525 million of cash and the assumption of approximately $1.4 billion of Colgate's outstanding net debt. Given existing cash balances and interim free cash flow, the company expects its net debt-to-LTM EBITDAX ratio at closing to be approximately 1.0x. The cash consideration and the repayment of Colgate's outstanding credit facility borrowings at closing are expected to be funded with cash on hand and borrowings under an upsized revolving credit facility. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second half of 2022. The company intends to provide detailed forward-looking guidance for the remainder of 2022 at or shortly after closing of the transaction. Upon closing, Sean Smith will serve as Executive Chair of the Board of Directors of the newly combined business, and Will Hickey and James Walter will lead the company as Co-CEOs and will serve on the Board of Directors. Matt Garrison, Centennial's current Chief Operating Officer, and George Glyphis, Centennial's current Chief Financial Officer, will continue to serve in their respective roles at the combined company. The combined company will be headquartered in Midland, with key positions filled by representatives from both companies. The Denver office will remain open for the foreseeable future to ensure continuity and continued operational success. The combined company will operate under a new name and stock ticker symbol, which are expected to be announced prior to closing. Following the merger, Centennial's Board of Directors will be expanded to eleven directors, consisting of Sean Smith, Will Hickey, James Walter, William Quinn and Robert Tichio, in addition to six independent directors. Immediately following the closing, existing Centennial shareholders will own approximately 53% of the combined company, and existing Colgate owners will own approximately 47% of the combined company. Centennial's largest shareholder, Riverstone, which currently owns approximately 25% of Centennial's outstanding shares, has executed a Voting and Support Agreement in connection with the transaction. The closing of the merger is subject to customary closing conditions, including approval by Centennial shareholders and regulatory approvals.

  • 01

    Jun

OTHER BREAKING NEWS FROM THE FLY

Downgrade
Lennar downgraded to Neutral from Outperform at Wedbush » 07:25
08/12/22
08/12
07:25
08/12/22
07:25
LEN

Lennar

$87.78 /

+0.47 (+0.54%)

Wedbush analyst Jay…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LEN Lennar
$87.78 /

+0.47 (+0.54%)

LEN Lennar
$87.78 /

+0.47 (+0.54%)

06:32 Today Wedbush
Lennar downgraded to Neutral from Outperform at Wedbush
07/12/22 JPMorgan
JPMorgan 'cautious and less constructive' on homebuilders, downgrades Lennar
07/12/22 JPMorgan
Lennar downgraded to Neutral from Overweight at JPMorgan
06/22/22 UBS
Lennar price target lowered to $106 from $108 at UBS
LEN Lennar
$87.78 /

+0.47 (+0.54%)

LEN Lennar
$87.78 /

+0.47 (+0.54%)

LEN Lennar
$87.78 /

+0.47 (+0.54%)

LEN Lennar
$87.78 /

+0.47 (+0.54%)

Hot Stocks
GreenLight Bioscences announces $109M financing » 07:25
08/12/22
08/12
07:25
08/12/22
07:25
GRNA

GreenLight Bioscences

$4.00 /

+0.09 (+2.30%)

GreenLight Biosciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GRNA GreenLight Bioscences
$4.00 /

+0.09 (+2.30%)

Hot Stocks
ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22
08/12/22
08/12
07:22
08/12/22
07:22
ARCW

ARC Group

$1.00 /

+ (+0.00%)

ARC Group Worldwide…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22
08/12/22
08/12
07:22
08/12/22
07:22
APTX

Aptinyx

/

+

Aptinyx announced results…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
APTX Aptinyx
/

+

APTX Aptinyx
/

+

05/18/22 Piper Sandler
Aptinyx price target lowered to $6 from $10 at Piper Sandler
04/14/22 H.C. Wainwright
Aptinyx price target lowered to $2 from $8 at H.C. Wainwright
04/08/22 BMO Capital
Aptinyx price target lowered to $6 from $12 at BMO Capital
04/08/22 Truist
Aptinyx price target lowered to $5 from $12 at Truist
APTX Aptinyx
/

+

APTX Aptinyx
/

+

Hot Stocks
Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20
08/12/22
08/12
07:20
08/12/22
07:20
UBX

Unity Biotechnology

/

+

UNITY Biotechnology…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

Downgrade
Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20
08/12/22
08/12
07:20
08/12/22
07:20
DBD

Diebold

$4.46 /

-0.13 (-2.83%)

JPMorgan analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DBD Diebold
$4.46 /

-0.13 (-2.83%)

DBD Diebold
$4.46 /

-0.13 (-2.83%)

07/08/22 Wedbush
Wedbush upgrades Diebold, sees sales and earnings positioned to improve
07/08/22 Wedbush
Diebold upgraded to Outperform from Neutral at Wedbush
05/10/22 JPMorgan
Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut
05/10/22 JPMorgan
Diebold downgraded to Neutral from Overweight at JPMorgan
DBD Diebold
$4.46 /

-0.13 (-2.83%)

DBD Diebold
$4.46 /

-0.13 (-2.83%)

Downgrade
Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20
08/12/22
08/12
07:20
08/12/22
07:20
PLXS

Plexus

$95.69 /

+0.88 (+0.93%)

JPMorgan analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PLXS Plexus
$95.69 /

+0.88 (+0.93%)

PLXS Plexus
$95.69 /

+0.88 (+0.93%)

07/29/22 Needham
Plexus price target raised to $105 from $93 at Needham
07/27/22 Benchmark
Plexus initiated with a Buy at Benchmark
06/07/22 Raymond James
Plexus upgraded to Outperform from Market Perform at Raymond James
01/28/22 Needham
Plexus price target lowered to $90 from $95 at Needham
PLXS Plexus
$95.69 /

+0.88 (+0.93%)

PLXS Plexus
$95.69 /

+0.88 (+0.93%)

Downgrade
Cognex downgraded to Underweight from Neutral at JPMorgan » 07:19
08/12/22
08/12
07:19
08/12/22
07:19
CGNX

Cognex

$48.48 /

+0.54 (+1.13%)

JPMorgan analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CGNX Cognex
$48.48 /

+0.54 (+1.13%)

CGNX Cognex
$48.48 /

+0.54 (+1.13%)

08/03/22 Needham
Cognex price target lowered to $50 from $60 at Needham
08/03/22 Cowen
Cognex price target lowered to $55 from $75 at Cowen
08/03/22 Stephens
Cognex downgraded to Equal Weight at Stephens on logistics demand deteriorating
08/03/22 Stephens
Cognex downgraded to Equal Weight from Overweight at Stephens
CGNX Cognex
$48.48 /

+0.54 (+1.13%)

CGNX Cognex
$48.48 /

+0.54 (+1.13%)

Recommendations
Six Flags price target lowered to $28 from $35 at Stifel » 07:18
08/12/22
08/12
07:18
08/12/22
07:18
SIX

Six Flags

$21.12 /

-4.685 (-18.16%)

Stifel analyst Steven…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SIX Six Flags
$21.12 /

-4.685 (-18.16%)

SIX Six Flags
$21.12 /

-4.685 (-18.16%)

05:44 Today KeyBanc
Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2
08/11/22 KeyBanc
Six Flags downgraded to Sector Weight from Overweight at KeyBanc
07/08/22 Citi
Six Flags downgraded to Neutral from Buy at Citi
06/24/22 Stifel
Six Flags price target lowered to $35 from $52 at Stifel
SIX Six Flags
$21.12 /

-4.685 (-18.16%)

SIX Six Flags
$21.12 /

-4.685 (-18.16%)

Hot Stocks
Unity Biotechnology announces anticipated milestones » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
UBX

Unity Biotechnology

/

+

UBX1325 24-week safety…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

Recommendations
Toast price target raised to $25 from $18 at KeyBanc » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
TOST

Toast

$18.12 /

-0.33 (-1.79%)

KeyBanc analyst Josh Beck…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TOST Toast
$18.12 /

-0.33 (-1.79%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

05/17/22 Mizuho
Toast price target lowered to $18 from $19 at Mizuho
05/13/22 Needham
Toast price target lowered to $21 from $38 at Needham
05/13/22 Canaccord
Toast price target lowered to $25 from $34 at Canaccord
05/09/22 Mizuho
Toast price target lowered to $19 from $23 at Mizuho
TOST Toast
$18.12 /

-0.33 (-1.79%)

  • 22
    Sep
TOST Toast
$18.12 /

-0.33 (-1.79%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

Hot Stocks
PLx Pharma announces survey data on VAZALORE 81 mg » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
PLXP

PLx Pharma

$2.59 /

+0.015 (+0.58%)

PLx Pharma, with its lead…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

03/15/22 BWS Financial
BWS drops coverage of PLx Pharma, says off Amazon again
12/07/21 Raymond James
Raymond James upgrades PLx Pharma on 'compelling entry point'
12/07/21 Raymond James
PLx Pharma upgraded to Outperform from Market Perform at Raymond James
11/12/21 JMP Securities
PLx Pharma reported strong quarter for Vazalore, says JMP Securities
PLXP PLx Pharma
$2.59 /

+0.015 (+0.58%)

Hot Stocks
Unity Biotechnology expects cash to fund operations through 1Q23 » 07:17
08/12/22
08/12
07:17
08/12/22
07:17
UBX

Unity Biotechnology

/

+

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

Recommendations
Illumina price target lowered to $300 from $480 at Stifel » 07:16
08/12/22
08/12
07:16
08/12/22
07:16
ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

Stifel analyst Daniel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

06:59 Today Citi
Illumina price target lowered to $200 from $220 at Citi
06:36 Today Baird
Illumina price target lowered to $215 from $306 at Baird
08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
07/14/22 Canaccord
Illumina merger challenge not reflection of merits, says Canaccord
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

Earnings
Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year » 07:16
08/12/22
08/12
07:16
08/12/22
07:16
UBX

Unity Biotechnology

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

UBX Unity Biotechnology
/

+

05/17/22 Citi
Unity Biotechnology price target lowered to $5 from $6 at Citi
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
UBX Unity Biotechnology
/

+

Recommendations
CS Disco price target lowered to $30 from $40 at Stifel » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

Stifel analyst J. Parker…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

06:15 Today BofA
CS Disco downgraded to Neutral from Buy at BofA
06:05 Today Canaccord
CS Disco downgraded to Hold from Buy at Canaccord
05:40 Today Cowen
Cowen cuts CS Disco to Market Perform as momentum hits 'big snag'
05:35 Today Cowen
CS Disco downgraded to Market Perform from Outperform at Cowen
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

  • 15
    Sep
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

Earnings
Real Good Food raises FY22 revenue $155M-$160M from $150M-$160M » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
RGF

Real Good Food

$6.93 /

-0.11 (-1.56%)

FY22 revenue consensus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

03/08/22 Roth Capital
Real Good Food initiated with a Buy at Roth Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Jefferies
Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months
11/30/21 Truist
Real Good Food initiated with a Buy at Truist
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

  • 05
    Nov
General news
Market Update: » 07:15
08/12/22
08/12
07:15
08/12/22
07:15
$ECON

Economic Data

/

+

Market Update: Stock…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Earnings
Venus Concept sees 2022 revenue $110M-$113M, consensus $126.82M » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
VERO

Venus Concept

/

+

The Company now expects…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VERO Venus Concept
/

+

VERO Venus Concept
/

+

06/24/22 BTIG
Venus Concept price target lowered to $5.50 from $7.00 at BTIG
11/12/21 Stifel
Venus Concept price target trimmed to $2 at Stifel after Q3 miss
VERO Venus Concept
/

+

Earnings
Venus Concept reports Q2 EPS (16c), consensus (7c) » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
VERO

Venus Concept

/

+

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VERO Venus Concept
/

+

VERO Venus Concept
/

+

06/24/22 BTIG
Venus Concept price target lowered to $5.50 from $7.00 at BTIG
11/12/21 Stifel
Venus Concept price target trimmed to $2 at Stifel after Q3 miss
VERO Venus Concept
/

+

Downgrade
Cellebrite downgraded to Market Perform at William Blair after guidance cut » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
CLBT

Cellebrite

$5.28 /

-0.4 (-7.04%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

06:06 Today William Blair
Cellebrite downgraded to Market Perform from Outperform at William Blair
05/16/22 Cowen
Cellebrite price target lowered to $13 from $17 at Cowen
05/13/22 Deutsche Bank
Cellebrite price target lowered to $10 from $11 at Deutsche Bank
02/24/22 JPMorgan
Cellebrite initiated with an Overweight at JPMorgan
CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

CLBT Cellebrite
$5.28 /

-0.4 (-7.04%)

Earnings
Real Good Food reports Q2 revenue $30.809M, consensus $32.12M » 07:14
08/12/22
08/12
07:14
08/12/22
07:14
RGF

Real Good Food

$6.93 /

-0.11 (-1.56%)

"I am pleased with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

03/08/22 Roth Capital
Real Good Food initiated with a Buy at Roth Capital
11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Jefferies
Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months
11/30/21 Truist
Real Good Food initiated with a Buy at Truist
RGF Real Good Food
$6.93 /

-0.11 (-1.56%)

  • 05
    Nov
Syndicate
Vigil Neuroscience announces $75M private placement finanicng » 07:13
08/12/22
08/12
07:13
08/12/22
07:13
VIGL

Vigil Neuroscience

$7.29 /

+0.13 (+1.82%)

Vigil Neuroscience…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

02/01/22 Morgan Stanley
Morgan Stanley starts Vigil at Equal Weight ahead of 2023 derisking catalysts
02/01/22 Stifel
Stifel starts Vigil Neuroscience at Buy with $24 price target
02/01/22 Guggenheim
Vigil Neuroscience initiated with a Buy at Guggenheim
02/01/22 Stifel
Vigil Neuroscience initiated with a Buy at Stifel
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

  • 07
    Jan
VIGL Vigil Neuroscience
$7.29 /

+0.13 (+1.82%)

Recommendations
Brilliant Earth price target raised to $10 from $8 at KeyBanc » 07:13
08/12/22
08/12
07:13
08/12/22
07:13
BRLT

Brilliant Earth

$6.44 /

-0.17 (-2.57%)

KeyBanc analyst Noah…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

07/22/22 Piper Sandler
Brilliant Earth downgraded to Neutral from Overweight at Piper Sandler
07/21/22 KeyBanc
KeyBanc transitions coverage of Global Brands & E-Commerce with cautious view
07/20/22 KeyBanc
Brilliant Earth initiated with an Overweight at KeyBanc
06/29/22 Raymond James
Brilliant Earth initiated with an Outperform at Raymond James
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

  • 23
    Sep
BRLT Brilliant Earth
$6.44 /

-0.17 (-2.57%)

Earnings
Aslan Pharmaceuticals reports Q2 EPS (4c) vs (2c) last year » 07:12
08/12/22
08/12
07:12
08/12/22
07:12
ASLN

Aslan Pharmaceuticals

/

+

Cash, cash equivalents…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
/

+

ASLN Aslan Pharmaceuticals
/

+

05/23/22 Piper Sandler
Aslan Pharmaceuticals price target lowered to $3 from $8 at Piper Sandler
09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
ASLN Aslan Pharmaceuticals
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.